Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LOXL2
REST API REST API
Homo sapiens
LOXL2 is differentially expressed in 300 experiments: 187 organism parts: lung, placenta, ... (185 more);, 295 disease states: normal, glioblastoma, ... (293 more);, 116 cell types 555 cell lines 38 compound treatments and 75 other conditions.
Synonyms WS9-14
Orthologs A6QQC7_BOVIN (Bos taurus)   Loxl2 (Rattus norvegicus)   ENSCING00000006336 (Ciona intestinalis)   lox2 (Drosophila melanogaster)   Loxl2 (Mus musculus)   LOXL2 (Gallus gallus)   loxl2 (Xenopus laevis)   LOXL2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, scavenger receptor activity, extracellular space, membrane, metal ion binding, extracellular region, oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor, cell adhesion, protein modification process, aging, electron carrier activity, copper ion binding, oxidation-reduction process
InterPro Term Lysyl_oxidase, Srcr_rcpt, Srcr_rcpt-rel
UniProt Accession Q9Y4K0, E5RFY0, E5RFE2, E5RJL2, E5RI22, E5RHH3
Search EB-eye ENSG00000134013
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
U251
2
E-MTAB-62, E-GEOD-20089
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC1937
2
E-MTAB-37, E-MTAB-62
HL-60
2
E-GEOD-5258, E-MTAB-37
Jurkat
2
E-GEOD-1880, E-MTAB-62
549 more value(s).


Cell type

studied in E-GEOD-21612, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (55 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-96, E-GEOD-3998
memory B cell
2
E-MEXP-2360, E-TABM-702
macrophage
2
E-GEOD-22373, E-GEOD-3982
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
whole blood
2
E-MTAB-25, E-GEOD-3026
110 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, ... (74 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-MTAB-62, E-MTAB-57, E-GEOD-3726
control
4
E-GEOD-3185, E-GEOD-20602, E-GEOD-20295, E-GEOD-16363
prostate carcinoma
4
E-GEOD-96, E-GEOD-3868, E-MTAB-62, E-MEXP-2034
glioblastoma
1
4
E-GEOD-4290, E-MTAB-37, E-MTAB-62, E-GEOD-6014, E-GEOD-4412 ... (5 experiments)
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
well-differentiated liposarcoma
2
E-GEOD-6481, E-MTAB-62
289 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-GEOD-15205, E-GEOD-5741, E-GEOD-697, ... (21 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-5741, E-GEOD-412, E-GEOD-5824, E-GEOD-4668, E-GEOD-697 ... (5 experiments)
baseline propofol
1
E-GEOD-4386
Cxcl12
1
E-GEOD-7307
N-nitrosodimethylamine
1
E-GEOD-6907
cadmium chloride 2.5-hydrate
1
E-GEOD-6907
oligomycin
1
E-MEXP-2285
32 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-17476, E-MEXP-421, E-GEOD-22593, E-GEOD-2292, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-10433, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-21750, E-GEOD-5824, E-GEOD-1460, E-GEOD-2487, E-GEOD-5820 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2508, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-MEXP-973, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.269 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM